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Schematic of a paramyxovirus  
From Abdisa and Tagesu,  J Vet Sci Technol 2017, 8:3 
 Mucosal administration (compared with 
inactivated vaccines). 
 Two different rAd doses. 
• Neutralizing antibodies, HIA 
• Lymphocyte proliferation assay, CTL, 
intracellular staining of cytokines. 
• Vaccination and challenge experiments 
(chicken) with NDV. 
• Cell mass, cell productivity. 
• Assays: HIA, neutralization, TCID50 and 
qPCR for virus quantification after 
challenge.  
• I ntracerebral pathogenicity index (ICPI) 
for randomly selected animals. 
 
 
Transfer / expression vectors constructed: 
pAdCMV-F, pAdCMV-HN, pAdCMV-F-HN: express the F and HN from NDV under the human cytomegalovirus immediate early enhancer. 
pAdCMV-GFP-F, pAdCMV-GFP-HN: express additionally the GFP under the human cytomegalovirus immediate early enhancer / promoter. 
pUC-βactin-F, pUC-βactin-HN, pUC-βactin-F-HN: express the F and HN from NDV under the human CMV enhancer + chicken β-actin promoter. 
 
Table 1. Adenoviral vectors generated / in construction. 
rAd5 generated Foreign coding gene Regulatory elements Status 
AdCMV-F NDV F protein 
Human cytomegalovirus immediate early 
enhancer / promoter (hCMV) 
Primary Ad stock generation in 
HEK293 cells established / rAds in 
amplification steps 
AdCMV-HN NDV HN protein 
AdCMV-F-HN NDV F and HN protein 
AdCMV-GFP-F NDV F protein + GFP 
AdCMV-GFP-HN NDV HN protein + GFP 
Adβact-F NDV F protein • Human CMV enhancer  
• Chicken β-actin promoter 
• Chimeric intron from chicken β-actin and 
rabbit β-globin 
Primary Ad stock generation in 
HEK293 cells to be established 
Adβact-HN NDV HN protein 
Adβact-F-HN NDV F and HN protein 
AdGFP GFP protein hCMV Primary stock established 




 The ND adenovirus vaccine constructed, to be produced at elevated cell densities in HEK293SF (expressing protective 
antigens from NDV), will provide an efficient and cost-effective platform able to address the limitations in efficacy and 
manufacturing associated with current conventional vaccines. 
 This promising platform technology for vaccine production and delivery will benefit the NVI of Ethiopia and will enhance its 
central role as the Pan African Veterinary Vaccine Control Center, producing and supplying vaccines to the Preferential Trade 
Area countries of Eastern, Western and Southern Africa. 
 
 
Figure 1. Effect of different culture media, feeding supplements 
and feeding  strategies on the cell density and viability of HEK293 
cells in suspension. 
• HyCell™ TransFx™-H Media (Hyclone Laboratories Inc) was supplemented with GlutaMAX™ at 4-6 mM and Kholliphor P188 at 0.1% .  
• Xell GM (Xell AG, Germany) was supplemented with GlutaMAX™ at 4-6 mM. 
Figure 2. Analysis by flow cytometry of GFP 
expression under different transfection conditions in 
HEK293 serum-free cells (for adenovirus stock 
generation). 
Figure 3. Expression analysis in HEK293 and HEK293 serum-free cultured cells of the recombinant F and HN antigens using polyclonal 
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1- Generating recombinant adenoviruses type 5 vectors expressing the 
F and HN antigens under different regulatory sequences. 
2- Establishing critical process parameters impacting the yield and 
quality of rAd5-ND vaccines at cells densities >6x106cells/mL. 
Representative strains isolated in 
recent years in Ethiopia belong to 
genotypes VI, and VII of class II.  
LaSota and B1 strains (included in 
current classic vaccines) were 
isolated many years ago and 
belong to genotype II, class II.  
Molecular Phylogenetic analysis and characterization of currently circulating strains in the 
region 





MEGA v7.0  
 Chicken/Ethiopia/14VIR4296-27/35828/2013
 Ethiopia/13VIR3936-27/2012_(F)









 2011_Ethiopia_ETH10073 fusion protein (F) and hemagglutinin-neuraminidase
 Chicken/Ethiopia/14VIR4296-24/19768/2013
 APMV-1/Chicken/Ethiopia/14VIR4296-24/19768/2013 fusion protein
 2011_Ethiopia_ETHMG1C fusion protein (F)
 2011_Ethiopia_ETHMG1C fusion protein (F) and hemagglutinin-neuraminidase
 2011_Ethiopia_ETH10065 fusion protein (F) and hemagglutinin-neuraminidase
 pigeon/Nigeria/VRD07-173/2007 fusion protein (F)
 dove/Nigeria/VRD07-163/2007
 APMV-1/Pigeon/Ethiopia/14VIR4296-4/2773/14/4/2014 fusion protein (F)
 chicken/Sudan/02/2005 fusion protein
 chicken/Sudan/05/2004 fusion protein
 NDV-EG-567F-2012 fusion protein
 APMV-1/chicken/Ethiopia/2011/12RS1402-39_57Cs/G fusion (F) gene
 APMV-1/chicken/Ethiopia/2012/12RS1402-67_50Ts/G fusion (F) gene
 China/NDV03-45-641/2003 fusion protein gene
 Newcastle disease virus fusion glycoprotein precursor-Beijing 1999
 Newcastle disease virus strain MG_MEOLA_08
 Newcastle disease virus fusion protein gene JAPAN-strain
 APMV-1/chicken/Ethiopia/2011/12RS1402-34_46Cs/G fusion (F) gene
 Newcastle disease virus fusion protein gene-Japan strain
 APMV-1/chicken/Ethiopia/2012/13RS176-4/41Cs/G fusion (F) gene
 NDV/chicken/Egypt/MR3/2003 fusion
 NDV/chicken/Behaira/Egypt/MR6/2012 fusion
 APMV-1/chicken/Ethiopia/2011/12RS1402-13_16Ts/Ay fusion (F) gene
 APMV-1/chicken/Ethiopia/2012/12RS1402-66_47Ts/G fusion (F) gene
 APMV-1/chicken/Ethiopia/2012/12RS1402-76_73Cs/M fusion (F) gene
 APMV-1/chicken/Ethiopia/2012/12RS1402-80_77Cs/F fusion (F) gene
 APMV-1/chicken/Ethiopia/2012/13RS176-5/10Ts/M fusion (F) gene
 virus isolate I-2progenitor
 Newcastle disease virus isolate I-2
 virus isolate 99-0868lo
 Newcastle disease virus strain MG_1992
 Newcastle disease virus B1


























Specific aims and methodologies 
 Poultry are a vital village livestock with important economic impact in sub-Saharan 
Africa. 
 Newcastle Disease (ND) is a highly contagious and endemic poultry infectious 
disease.  
Recurrent outbreaks provoke heavy losses every year.  
ND virus (NDV) is a negative-sense single-stranded RNA virus from the genus 
Avulavirus, family Paramyxoviridae.  
Current NDV vaccines are only partially protective and are produced in specific 
pathogen-free chicken embryonated eggs, whose supply is expensive and problematic. 
 A recombinant adenovirus-based Foot and Mouth Disease vaccine has been 
licensed for production and use in US in emergency situations. 
3- Defining a process operating strategy allowing high-cell 
density productive infection in bioreactors as well as a 
downstream processing and formulation. 
4- Performing  animal studies on the immunogenicity 
(humoral, cell-mediated responses to the rAd-ND) and 
comparative studies on vaccine efficacy.  
• Basal serum-free media, additives. 
• Kinetics of growth, nutrient 
consumption, product synthesis. 
• Vaccine product: infectivity, antigen 
activity. 
• Cell mass, cell productivity. 




Amplification of F gene fragments 
from Ethiopian NDV field isolates 
Results 
• Scale-up in bioreactors:        1-3L       20L. 
• Physiological changes, nutritional requirements, 
feeding rate. 
• Downstream processing. 
• Thermal stabilization        additives. 
• Formulations for: oral drench /eye drop. 
• Lyophilization defined as primary choice for eye-
drop and oral presentations. 
 
5- Evaluate vaccine stability relative to live NDV vaccines and perform toxicology studies in non-target animals. 
6- To conduct sustainable technology transfer for building capacity at the NVI, Ethiopia.  
Maximized rAd5 product yields in HEK293 serum free cells 
Challenge  
2 weeks p.i. 
• Toxicology studies and biodistribution (GFP-expressing rAds) in non-target 
animals. 
• TCID50 and qPCR for virus quantification. 
• Develop SOPs required, repository and common access. 
• Scale-up of the process validation and document Process Analytical 
Technologies. 
• Technology transfer to NVI, Ethiopia. 
Concluding remarks 
Cells transfected with pAdCMV-GFP-F 
vector 
Cells lysates from serum free HEK293 
transfected cells in suspension: 
Dot blot using polyclonal serum anti-NDV 
1- HEK293 cells transfected with pAdCMV-GFP-F. 
2- HEK293 cells transfected with pAdCMV (GFP). 
3- HEK293SF cells transfected in suspension with 
pAdCMV-F. 
4- HEK293SF cells transfected in suspension with 
pAdCMV-HN. 
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(GFP expression verified by flow cytometry). 
Cells lysates from adherent HEK293 transfected cells: 
 
1- HEK293 cells transfected with pAdCMV-GFP-HN. 
2- HEK293 cells transfected with pAdCMV-GFP-HN (cells in PFA 2%). 
3- HEK293 cells transfected with pAdCMV-F. 
4- HEK293 cells transfected with pAdCMV-HN. 
5- HEK293 cells transfected with pAdCMV-GFP-F (cells in PFA 2%). 
6- HEK293 cells transfected with pAdT-GFP (GFP verified by flow 
cytometry). 
 
Panel A) Polyclonal serum anti-NDV 
Panel B) Monoclonal anti-HN antibody 
  
Implement at the National Veterinary Institute (NVI), Ethiopia, a technological platform for the 
production of veterinary vaccines, by developing a recombinant non-replicating adenoviral vector 
















































HEK293SF Xell GM (0.25M) 
Xell GM+FS (0.25M) 
HyCell TransFx-H (0.25M) 
HyCell TransfFx-H + Cell 
Boost 
Viability Xell GM (0.25M) 
Viability Xell GM+FS 
(0.25M) 
Viability HyCell TransFx-H 
Viability HyCell TransFx-H + 
Cell Boost 
